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Abstract 
The majority of the leukocytes cross the endothelial lining of the vessels through cell-cell 
junctions. The junctional protein Vascular Endothelial (VE)-cadherin is transiently 
re-distributed from sites of cell-cell contacts during passage of leukocytes. VE-cadherin is 
part of a protein complex comprising p120-catenin and beta-catenin as intracellular partners. 
Beta-catenin connects VE-cadherin to alpha-catenin. This VE-cadherin-catenin complex is 
believed to dynamically control endothelial cell-cell junctions and to regulate the passage of 
leukocytes, although not much is known about the role of alpha- and beta-catenin during the 
process of transendothelial migration (TEM). In order to study the importance of the inter-
action between alpha- and beta-catenin in TEM, we used a cell-permeable version of the 
peptide encoding the binding site of alpha-catenin for beta-catenin (S27D). The data show 
that S27D interferes with the interaction between alpha- and beta-catenin and induces a 
reversible decrease in electrical resistance of the endothelial monolayer. In addition, S27D 
co-localized with beta-catenin at cell-cell junctions. Surprisingly, transmigration of neutro-
phils across endothelial monolayers was blocked in the presence of S27D. In conclusion, our 
results show for the first time that the association of alpha-catenin with the cadherin-catenin 
complex is required for efficient leukocyte TEM.   
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Introduction 
Vascular Endothelial Cadherin (VE-cadherin, 
Cadherin-5) is specifically expressed in endothelial 
cells and localizes at adherens junctions. VE-cadherin 
is a calcium-dependent and homophilic transmem-
brane adhesion molecule that bridges adjacent endo-
thelial cells. It associates to the armadillo-family pro-
teins beta- and gamma-catenin that bind the ac-
tin-binding protein alpha-catenin [1,2]. Together, 
these proteins form the so-called cadherin-catenin 
complex. Because VE-cadherin-mediated cell-cell 
junctions hold the endothelial cells tightly together, 
the endothelial layer functions as a barrier for mac-
romolecules and leukocytes and thereby protects the 
underlying tissue from damage. However, under 
certain (pathologic) conditions, such as inflammation, 
traffic of leukocytes across the endothelial layer 
through the cell-cell junctions is required. To avoid 
leakage of the endothelial layer, the opening and 
closure of VE-cadherin-mediated junctions is tightly 
regulated through controlled intracellular signaling 
[3-5]. We and others have previously reported that 
inhibition of VE-cadherin function by the use of 
blocking antibodies promotes transendothelial mi-
gration of neutrophils and CD34+ cells in vitro and in Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
696
vivo  [6-8], suggesting that VE-cadherin mediates 
transendothelial migration of leukocytes.  
The catenins are thought to play an important 
role in the regulation of VE-cadherin function. Lam-
pugnani and co-workers showed that tyrosine phos-
phorylation of VE-cadherin and associated catenins is 
increased in loosely confluent endothelial monolay-
ers, whereas the phosphorylation is diminished in 
tightly confluent monolayers [9]. Ozawa and Kemler 
showed that increased levels of tyrosine phosphory-
lation, induced by pervanadate promote the dissocia-
tion of alpha-catenin from the cadherin-catenin com-
plex [10]. Moreover, their results indicated that the 
binding of alpha-catenin to the cadherin-catenin 
complex is a prerequisite for proper functioning cad-
herin-catenin complex, since an 
E-cadherin-alpha-catenin chimera was insensitive to 
pervanadate treatment leaving E-cadherin 
trans-interactions intact, whereas cells expressing the 
normal cadherin-catenin complex, including 
beta-catenin, showed loss of cell-cell contact after 
pervanadate treatment [10]. 
  Several papers have shown that beta- and al-
pha-catenin become transiently and locally dispersed 
from cell-cell contacts upon passage of leukocytes 
[11,12]. However, it is unclear if the interaction be-
tween the catenins is necessary for optimal transen-
dothelial migration.  
In this study, we used a peptide encoding the 
beta-catenin binding site of alpha-catenin (S27D) [13], 
fused to a cell-permeable protein transduction do-
main and tagged with biotin to study the role of the 
alpha- and beta-catenin interaction in transendothelial 
migration of leukocytes. The results show that S27D 
binds beta-catenin and dissociates it from al-
pha-catenin, which is accompanied by a reversible 
drop of the electrical resistance of the endothelial cell 
monolayer. In addition, we show that the loss of 
beta-catenin from alpha-catenin, induced by the pep-
tide, decreases leukocyte transmigration across the 
endothelium, despite the fact that the electrical resis-
tance is reduced. 
These data indicate that the passage of leuko-
cytes through the cell-cell junctions requires the 
presence of alpha-catenin in the cadherin-catenin 
complex in order to modulate endothelial cell-cell 
junctions. This report is the first to show that al-
pha-catenin plays an important role in leukocyte 
transendothelial migration. 
Methods 
Reagents and Abs - mAb to beta-catenin, PY20, 
p120-catenin, VE-cadherin, plakoglobin and An-
nexin-V-FITC were purchased from Transduction 
Laboratories (Becton Dickinson Company, Amster-
dam, The Netherlands). mAb to alpha-catenin was 
purchased from Zymed (South California, CA). Rab-
bit polyclonal Abs to alpha- and beta-catenin were 
purchased from Santa Cruz Biotechnology (CA, USA). 
Actin mAb was purchased from Sigma-Aldrich 
(Zwijndrecht, the Netherlands). ICAM-1 and 
VCAM-1 Abs were purchased from R&D systems 
(Abingdon, UK). Recombinant Tu-
mor-Necrosis-Factor (TNF)-α was from PeproTech 
(Rocky Hill, NJ); Texas-Red Phalloidin, ALEXA 
488-labelled GαM-Ig, ALEXA 568-labelled GαM-Ig, 
ALEXA 568-labelled GαR-Ig, ALEXA 488-labelled 
GαR-Ig and ALEXA 488-labelled streptavidin secon-
dary Abs were from Molecular Probes (Leiden, The 
Netherlands) and all used in a 1:500 dilution. 
PECAM-1 Ab (Hec170) and Fibronectin (FN) were 
obtained from Sanquin (Amsterdam, The Nether-
lands). Propidium iodide was purchased from Cal-
biochem (San Diego, CA). 
Cell cultures - Primary pooled HUVEC were 
purchased from Lonza (Allendale, USA) and cultured 
in FN-coated culture flasks (NUNC, Life Technolo-
gies) in EGM2 containing singlequots (Lonza) and 
used until passage 9. Freshly isolated endothelial cells 
from umbilical cord, according to Brinkman et al. [14], 
were cultured similarly and used until passage 5. The 
difference in passage time may be due to donor 
variation and that Lonza HUVECs were pooled. In 
TEM assays, endothelial cells were pre-treated with 
10ng/ml TNF-α overnight as indicated. All cell lines 
were cultured at 37°C and at 5% CO2. Primary neu-
trophils were isolated as described previously [15]. 
Measurement of apoptosis - Apoptosis of HUVECs 
was measured by flow cytometry with the an-
nexin-V-fluorescein isothiocyanate (FITC)/propidium 
iodide (PI) apoptosis assay kit (Bender Medsystems, 
Vienna, Austria) as described [15].  Confluent HU-
VECs were treated as indicated and detached with 
10mM EDTA. Next, cells were centrifuged mildly and 
washed once in ice-cold HEPES medium with 2.5 mM 
Ca2+. All further steps were performed in this medium 
on ice. The cells were then incubated for 45 minutes 
with annexin-V-FITC, 1:250, which specifically binds 
phosphatidylserine residues on  the cell membrane. 
During the last 10  minutes PI was added to a final 
concentration of 1 µg/mL. PI is a fluorescent dye that 
intercalates into DNA once the cell membrane has 
become permeable. After incubation, the cells were 
washed once and analyzed by FACScan  (Becton 
Dickinson, San Jose, CA). Viable cells were defined as 
negative for Annexin-V-FITC and PI staining. Cell 
survival was expressed as a percentage of viable cells 
in relation to the total number of counted cells.  Int. J. Biol. Sci. 2009, 5 
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S27D peptide – The peptide encodes 27 
amino-acids, which reflect the binding site of al-
pha-catenin to beta-catenin, according to Huber et al 
[13] (Figure 1). The peptide was synthesized at the 
Netherlands Cancer Institute (Amsterdam, The 
Netherlands) as a fusion with a protein transduction 
domain to make it cell-permeable [16] and tagged 
with biotin. Peptide stocks were in DMSO at 
100mg/mL. As control peptide, the transduction do-
main, tagged with biotin and dissolved in DMSO was 
used. (See also previous report: [16]). The peptides, 
either S27D or control, was used at a final concentra-
tion of 5μg/mL and added to the culture medium for 
indicated time periods. 
 
 
Figure 1. Schematic overview of the cell-permeable S27D 
peptide.  The amino acid sequence of the 
beta-catenin-binding domain in alpha-catenin is shown. The 
peptide is N-terminally fused to a protein transduction 
domain and tagged with a biotin as indicated. Glycine (-G-) 
is used as a linker. 
 
 
 
 Immunofluorescence  - HUVEC were cultured on 
FN-coated glass cover slips, fixed and im-
muno-stained as described [8] with Abs as indicated. 
Staining was followed by secondary staining with 
fluorescently labeled Abs. Images were recorded with 
a ZEISS LSM510 confocal microscope with appropri-
ate filter settings. Cross-talk between the green and 
red channel was avoided by use of sequential scan-
ning. 
 Flow  Cytometry  - HUVEC were cultured on 
FN-coated glass cover slips, treated with TNF-α 
overnight and incubated for 30 minutes with S27D, 
control peptide or DMSO. Next, cells were 
trypsinized, fixed, stained as indicated, and analyzed 
by FACS CANTO II (Becton Dickinson). 
 Electric Cell-substrate Impedance Sensing (ECIS) - 
Endothelial cells were added at 100.000 cells per well 
(0.8cm2) to a FN-coated electrode-array, containing 
L-cysteine-pretreated 10 gold-electrodes per array, 
and grown to confluency. After the electrode-check of 
the array and the basal trans-electrical resistance 
(TER) of the endothelial monolayer, the peptide or 
DMSO were added and TER was measured on line at 
37°C at 5% CO2 with the ECIS-Model-100 Controller 
from BioPhysics, Inc. (Troy, NY). Detailed  
 Immunoprecipitation and Western blot analysis - 
Cells were grown to confluency on FN-coated dishes 
(50cm2), washed twice gently with ice-cold Ca2+-and 
Mg2+-containing PBS and lysed in 300μL of lysis 
buffer (25mM Tris, 150mM NaCl, 10mM MgCl2, 2mM 
EDTA, 0.02% SDS, 0.2% deoxycholate, 1% NP-40, 
0.5mM orthovanadate with the addition of fresh 
protease-inhibitor-cocktail tablets (Boehringer) pH 
7.4). After 10 minutes on ice, cell lysates were col-
lected and pre-cleared for 30 minutes at 4°C with 
Streptavidin beads (Sigma-Aldrich, 15μl for each 
sample). The supernatant, cleared by centrifugation 
(14.000*g, 5 minutes at 4°C) was incubated with 
15μl protein Streptavidin beads that were coated 
with the biotin-tagged S27D or the control peptide, 
for 1h at 4°C under continuous mixing. The beads 
were washed 3 times in lysis buffer and proteins 
were eluted by boiling in SDS-sample buffer con-
taining 4% 2-mercaptoethanol (Bio-Rad). The samples 
were analyzed by 10% SDS-PAGE. Proteins were 
transferred to 0.45 μm nitro-cellulose (Schleicher and 
Schnell Inc., NH) and the blots were first blocked with 
5% (w/v) low-fat milk in Tris-Buffered Saline 
Tween-20 (TBST) for 1h, subsequently incubated at 
room temperature with the appropriate Abs for 1h, 
followed by 30 minutes incubation with 
HRP-conjugated secondary Abs at RT. Between the 
various incubation steps, the blots were washed 5 
times with TBST and finally developed with an en-
hanced chemiluminescence (ECL) detection system 
(Amersham). For the Triton-X100 insoluble fractions, 
HUVECs were lysed for 10 minutes on ice using 
25mM Tris, 150mM NaCl, 10mM MgCl2, 2mM EDTA, 
1% Triton-X100, 0.5mM orthovanadate with the addi-
tion of fresh protease-inhibitor-cocktail tablets at pH 
7.4. Next, cells were scraped from the culture plate 
and centrifuged at 14.000*g, 10 minutes at 4°C to 
separate the soluble from the insoluble fraction. Frac-
tions were diluted in SDS-sample buffer containing 
4% 2-mercaptoethanol and analyzed by Western blot-
ting. As a control, RhoGDI, as a cytosol marker, was 
used in the Triton-X100 insoluble fraction to deter-
mine the isolation procedure. 
 Transendothelial  migration  assay - Assays were 
performed in 6.5-mm Transwell plates with 5-µm pore Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
698
filters. HUVEC were plated  at 20,000–30,000 
cells/Transwell on FN-coated filters.  The adherent 
cells were cultured for 2–3 days to obtain confluent 
endothelial  monolayers and pre-treated overnight 
with TNF-α. 100.000 Neutrophils, isolated as de-
scribed previously [7], or HL60 cells, differentiated by 
1.3% DMSO for 3-5 days as described previously [8], 
were added to the upper compartment in 0.1 ml of 
assay medium, and 0.6 ml of assay medium with or 
without 50ng/mL human CXCL12 (SDF-1α) (Strath-
mann Biotech, Hannover, Germany) or 10nM fMLP 
(Sigma) was added to the lower compartment. 
Transwells were incubated at 37°C, 5% CO2, for 1h for 
neutrophils and 4h for HL60 cells. Cells that migrated 
to the lower compartment were collected and FACS 
analysis was used to determine how many cells mi-
grated, as described before [8]. After the assay, the 
filters were fixed and stained with Texas-Red phal-
loidin to confirm HUVEC monolayer confluency by 
confocal laser scanning microscopy. 
Statistics - Student’s t-test for paired samples 
(two-tailed) was used independent samples was used 
where indicated. 
 
 
Results 
The formation of adherens junctions and the in-
tegrity of endothelial monolayers are controlled by 
trans-interactions between VE-cadherin molecules on 
adjacent endothelial cells [2]. Previous studies have 
shown that VE-cadherin-mediated cell-cell junctions 
are transiently disrupted to allow leukocyte TEM 
[4,8]. Beta-catenin, which associates to the intracellu-
lar tail of VE-cadherin and alpha-catenin, which binds 
to beta-catenin, contribute to the connection of 
VE-cadherin with the cortical actin cytoskeleton [2]. 
However, the role for the catenins in leukocyte TEM is 
unclear. Huber and co-workers defined the domain 
by which alpha-catenin binds beta-catenin [15]. They 
used this domain to construct a peptide, S27D, that 
specifically binds beta-catenin. To study if this do-
main is important in TEM, we constructed a bioti-
nylated fusion peptide of S27D with a pro-
tein-transduction domain (PTD), which renders the 
peptide cell-permeable [13] (Figure 1). PTD is origi-
nally cloned from the TAT-HIV sequence by Na-
gahara et al. [17]. It exists of a hydrophobic amino acid 
stretch and is frequently used in studies to deliver 
peptides into mammalian cells [18]. However, the 
delivery process is unknown [19]. Nevertheless, small 
peptides such as S27D are delivered with high effi-
ciency into mammalian cells [20]. 
 
 
 
 
Figure 2. Effects of S27D on viability on endothelial cells. (A) 
TNF-α-stimulated HUVEC were treated for 30 minutes 
with S27D (5μg/mL), control peptide (CTRL) or DMSO and 
subsequently trypsinized, fixed and stained with An-
nexin-V-FITC and Propidium iodide (PI). Plots show that 
after S27D treatment, 77% of the cells were negative for 
Annexin-V. After DMSO and control peptide (CTRL) 
treatment, respectively 89% and 88% of the cells were 
negative. All cells were negative for PI, showing that the 
treatment did not induce necrosis. Neutrophils (PMN) 
were left overnight (O/N) and used as positive Annexin-V 
control. Only 15% of the PMNs were Annexin-V negative. 
(B) Effect of S27D on apoptosis of endothelial cells at dif-
ferent time points are analyzed using Annexin-V-FITC la-
beling. Experiment is carried out three times. Data are 
mean ± SEM. (C) HUVEC were treated as described under 
A. Expression of ICAM-1, VCAM-1, PECAM-1 and 
VE-cadherin was measured by flow cytometry analysis and Int. J. Biol. Sci. 2009, 5 
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expressed as Mean fluorescent Intensity (MFI) arbitrary 
units on the Y-axis. S27D was incubated for different time 
points as indicated. VE-cadherin expression is increased 
after overnight treatment with S27D. Experiment was 
carried out three times in triplicate. Data are mean ± SEM. 
*p<0.05. 
 
Firstly, we tested if S27D affected the viability of 
the endothelial cells. Using flow cytometry to measure 
Annexin-V binding, a marker for early apoptosis, we 
found that the majority of the endothelial cells (77%) 
were Annexin-V negative after 30 minutes S27D 
treatment compared to approximately 88% of the cells 
treated with DMSO or control peptide (Figure 2A). All 
cells remained propidium iodide-negative, showing 
that the treatment did not induce necrosis (Figure 2A). 
Additional analysis revealed no increase in apoptosis 
in S27D-treated endothelial cells, compared to 
DMSO-treated cells (Figure 2B). Moreover, the pres-
ence of S27D for up to 60 minutes did not change the 
morphology of the endothelial cell monolayer, as was 
judged by real-time phase-contrast recordings (data 
not shown). These data show that the peptide did not 
induce apoptosis or gross morphological changes in 
these cells. In addition, the surface expression of the 
adhesion molecules ICAM-1 and VCAM-1, as well as 
of PECAM-1, was unaltered after S27D treatment 
(Figure 2C). Interestingly, VE-cadherin expression 
was increased after S27D treatment. Whether this is 
the result of reduced internalization of cell-surface 
VE-cadherin is unclear. Xiao and colleagues showed 
that p120-catenin regulates the internalization of 
VE-cadherin [21]. Therefore, we tested if the associa-
tion of p120-catenin to VE-cadherin increased after 
S27D treatment. However, our results showed that 
S27D did not alter the interaction between these pro-
teins (Supplemental figure 1).   
To confirm that S27D binds to beta-catenin, a 
pull-down experiment with endothelial cell lysates 
was performed. This experiment showed that S27D, 
but not the control peptide, binds to beta-catenin, but 
not the actin binding protein ezrin (Figure 3A). In 
addition, the peptide also binds to plakoglobin (Fig-
ure 3A). In the pull down experiment, also 
p120-catenin and VE-cadherin are found (Figure 3A). 
This showed that the peptide can precipitate the intact 
VE-cadherin complex. To elucidate if the peptide in-
terferes with the interaction between beta-catenin and 
alpha-catenin, an immuno-precipitation (IP) assay for 
alpha-catenin was performed. Intact endothelial cells 
were pre-treated with the cell-permeable S27D or 
control peptide for 30 minutes after which the cells 
were lysed and alpha-catenin was immunoprecipi-
tated. IPs were analyzed by Western blotting for 
binding of beta-catenin to alpha-catenin, which 
showed that S27D reduced the association between 
alpha- and beta-catenin in intact endothelial cells 
(Figure 3B). Also plakoglobin was precipitated by 
S27D. To study if S27D induced a shift of the cell-cell 
junction proteins form the cytoskeletal fraction (Tri-
ton-X-100 insoluble fraction) to the cytosolic fraction 
(Triton-X-100 soluble fraction), we analyzed the pellet 
fraction after S27D treatment by Western blotting. No 
changes in the levels of VE-cadherin, plakoglobin, 
alpha-catenin or actin in the cytoskeletal fraction after 
S27D treatment can be measured, as was judged by 
analyzing the Triton-X100-insoluble fraction by 
Western blotting (Supplemental figure 2). 
 
 
Figure 3. S27D binds to beta-catenin and dissociates al-
pha-catenin from beta-catenin. (A) HUVEC lysates were 
incubated with S27D and pull-down assays as described in 
Methods were performed. The samples were analyzed by 
Western blotting, which showed that S27D bound to 
beta-catenin, plakoglobin, p120-catenin and VE-cadherin. 
Control peptide (CTRL), encoding only the protein trans-Int. J. Biol. Sci. 2009, 5 
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duction domain, or empty beads did not bind to the proteins. Right lane shows protein expression in total cell lysate. Ezrin 
(bottom panel) did not bind to the peptide. (B) HUVEC were treated for 30 minutes with S27D or control peptide (CTRL) 
and then lysed. Subsequently, alpha-catenin was immuno-precipitated (I.P.) as described in Methods. Western blot was 
immunostained for beta-catenin (I.B.), which showed that S27D dissociates beta-catenin from alpha-catenin, but that the 
control peptide did not interfere with this interaction. Also plakoglobin binding to alpha-catenin was reduced after S27D 
administration. Lower panels showed controls for IP of alpha-catenin and expression of beta-catenin, plakoglobin and actin 
in total cell lysates. Data are representative for three independent experiments. Blots are scanned and the intensity were 
quantified using ImageJ and plotted in the graphs on the right. Results show that S27D significantly reduces the binding of 
beta-catenin or plakoglobin to alpha-catenin. Data are mean ± SEM. *p<0.05. 
 
To study the localization of S27D, endothelial 
cells were incubated for 30 minutes with S27D and 
then fixed and permeabilized for fluorescent strepta-
vidin-based image analysis. Using this approach, we 
confirmed that the biotin- and PTD-tagged S27D en-
tered live cells and, in contrast to the control peptide 
accumulated at cell-cell junctions where it co-localized 
with beta-catenin (Figure 4). Alpha-catenin showed a 
more diffuse pattern away from the cell-cell junctions, 
indicating that S27D removed alpha-catenin from the 
cell-cell junctions (Figure 4). VE-cadherin and 
p120-catenin also showed a diffuse staining, although 
the majority of the proteins remained localized at 
cell-cell junctions. Finally, S27D did not induce major 
changes in F-actin levels or its distribution (data not 
shown). To study if the trans-electrical resistance 
(TER) of the endothelial monolayer is affected by 
S27D, TER was measured in time using ECIS (electri-
cal cell-substrate impedance sensing) [20]. When the 
endothelial monolayer reached confluency, the basal 
resistance was approximately 20 Ohms/cm2. At that 
time, S27D was added to the cell monolayers. After a 
few minutes, TER started to decline and reached 
lowest levels at approximately 4.5h after addition of 
S27D, which corresponded with approximately 16.2 
Ohms/cm2 (Figure 5A). Interestingly, VE-cadherin 
was still localized at cell-cell junctions at this time 
point, as was analyzed in parallel by confocal mi-
croscopy (Figure 5A). To test if S27D affected the ty-
rosine phosphorylation level of VE-cadherin, 
VE-cadherin was immunoprecipitated and the sam-
ples were analyzed by Western blot using phospho-
tyrosine antibodies. No change in phos-
pho-VE-cadherin levels could be detected in cells that 
have been treated with S27D for 30 minutes (Supple-
mental figure 3A). Next, the medium was refreshed 
and S27D was washed out. TER recovered and 
reached a plateau level, which was equal to the con-
trol peptide-treated cells at approximately 12 hours 
after wash-out (Figure 5A). Biochemical analysis of 
the VE-cadherin complex showed that the interaction 
between beta-catenin and alpha-catenin is restored 
after wash-out (Figure 5B). Alpha-catenin was also 
found in the VE-cadherin immunoprecipitate, indi-
cating that the VE-cadherin-catenin complex was re-
stored (Figure 5B). However, no change in 
VE-cadherin tyrosine phosphorylation is detected 
upon wash-out (Supplemental figure 3B). These re-
sults showed that the S27D peptide induced a re-
versible drop in TER and in the dissociation of the 
VE-cadherin complex, which is independent of 
VE-cadherin tyrosine phosphorylation. S27D did not 
affect the cell-matrix adhesion or viability, since all 
cells still adhered to the electrode and no floating cells 
were detected. Finally, addition of S27D upon plating 
of the cells to the fibronectin-coated electrodes did not 
affect the initial adhesion and cell-spreading [23] or 
the adhesion to the matrix (Figure 5C). Thus, S27D 
does not interfere with endothelial cell adhesion and 
spreading, but selectively targets the composition of 
the VE-cadherin-catenin complex and thereby junc-
tional integrity. 
The majority of leukocytes that cross endothelial 
monolayers use the paracellular route, i.e. through the 
cell-cell junctions [23,24]. Several groups, including 
ours, have shown that VE-cadherin is locally dis-
persed at sites where leukocytes transmigrate [4,8]. 
Also beta- and alpha-catenin are locally dispersed 
from sites of cell-cell contact upon passage of leuko-
cytes [11,12]. However, it is not clear to what extent 
alpha-catenin contributes to the process of transen-
dothelial migration. To study this, transendothelial 
migration assays using Transwells were performed 
and the effect of S27D was analyzed. Primary neu-
trophils were isolated and allowed to migrate across 
TNFα-stimulated HUVEC to the chemokine CXCL12. 
The results show that S27D significantly reduced the 
extravasation of neutrophils across endothelial cells 
(Figure 6A). Spontaneous migration of neutrophils 
was also reduced when endothelial cells were pre-
treated with S27D, albeit to a limited extent (Figure 
6A). Migration of differentiated HL60 cells across 
endothelial monolayers was also significantly blocked 
in the presence of S27D (Figure 6B). To exclude an 
effect of S27D on the migration efficiency of the leu-
kocytes, S27D was tested in a chemotaxis assay. Tran-
swell-filters were coated with fibronectin and HL60 
cells were allowed to migrate to CXCL12 in the pres-Int. J. Biol. Sci. 2009, 5 
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ence or absence of S27D. Figure 6C shows that S27D 
did not affect the chemotactic capacity of the leuko-
cytes, indicating that the effect of S27D observed in 
Figure 6A and 6B was due to the dissociation of alpha- 
and beta-catenin in the endothelial cells. The adhesion 
of neutrophils to pretreated endothelial cells was not 
affected by the presence of S27D (data not shown). 
Washing away S27D resulted in restoration of the 
cell-cell junctions and of the S27D-induced inhibition 
of neutrophil TEM (Figure 6D). Together, these data 
indicate that the presence of alpha-catenin in the 
VE-cadherin-catenin complex is required for efficient 
passage of leukocytes across endothelial monolayers. 
 
 
Figure 4. S27D induces diffused localization of alpha-catenin. Endothelial cells were cultured and grown to confluency on 
FN-coated glass cover slips and subsequently incubated with the control peptide (CTRL; upper panel) or S27D (lower 
panels) for 30 minutes. Next, cells were fixed, permeabilized and stained with streptavidin to detect S27D (green) and Abs 
to beta-catenin, VE-cadherin, alpha-catenin and p120-catenin (red). Merge shows the co-localization of S27D and the in-
dicated proteins in yellow (Arrowheads). Bar, 20μm.  Int. J. Biol. Sci. 2009, 5 
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Figure 5. S27D reduces TER of endothelial 
monolayers.  (A) HUVECs were cultured to 
confluency on 10E golden ECIS electrodes 
and TER was recorded in real-time as de-
scribed in Methods. Cells were treated as 
described in Figure 3. The electrical resistance 
is normalized and set as 1. Peptides remained 
present throughout the experiment. Results 
show that S27D, added at T=0 induces a drop 
in electrical resistance, which recovers after 
the peptide was washed-out (arrow and 
dashed line at 4.5 hours). Data are the average 
of triplicates of one experiment and are rep-
resentative of four experiments, performed in 
triplicate. Lower panels show localization of 
VE-cadherin in green at cell-cell junctions 
after 4 hours of S27D treatment. F-actin is 
shown in red and co-localization appears in 
yellow in the merged image. Bar, 50μm. (B) 
HUVEC were treated for 4.5 hours with 
S27D (No Wash) or S27D was washed away 
after 4.5 hours and left untreated overnight 
(Wash 18h). Next, alpha-catenin or 
VE-cadherin was immuno-precipitated (I.P.) 
and Western blot membrane was stained as 
indicated (I.B.). Results showed that washing 
away S27D restored the VE-cadherin com-
plex.  (C) Upon plating, HUVECs were 
treated with S27D (open circles) or control 
peptide (closed circles), seeded on 10E-gold 
electrodes and cell-spreading was recorded in 
real-time using ECIS as described in Methods. 
Peptides remained present throughout the 
experiment. Results show that S27D did not 
affect HUVEC spreading on FN-coated sur-
faces. 
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Figure 6. S27D reduces TEM of leukocytes. (A) Primary 
human neutrophils were allowed to migrate toward 
50ng/mL CXCL12 for 1h across TNF-α-pre-treated 
HUVEC that are cultured on a FN-coated 5-μm pore 
Transwell filters. Chemotaxis was quantified as described in 
Methods. Endothelial cells were pre-treated for 30 minutes 
with DMSO or with S27D, which remained present 
throughout the experiment. Neutrophil migration was 
blocked significantly in the presence of the peptide. Data 
represent mean ± SEM from triplicates. Experiment was 
repeated three times. *, p<0.05. (B) Differentiated HL60 
cells were allowed to migrate across TNFα-treated HUVEC 
as described under (A). HL60 migration was blocked sig-
nificantly in the presence of S27D. Data represent mean ± 
SEM from triplicates. Experiment was repeated three times. 
*, p<0.01. (C) Differentiated HL60 cells were allowed to 
migrate across fibronectin-coated Transwell filters toward 
50ng/mL CXCL12 for 2 hours in the absence or presence of 
S27D. Chemotaxis was quantified as described in Methods. 
Data represent mean ± SEM from triplicates. Experiment 
was repeated three times. (D) Primary human neutrophils 
were allowed to migrate as described under A, but as 
chemokine 10 nM fMLP was used. HUVECs were treated 
with S27D for 30 minutes, 4.5 hours present during the 
assay, or washed away after 4.5 hours and left untreated for 
O/N. S27D inhibited TEM significantly with 4.5 hours but 
not when washed away. Data represent mean ± SEM. Ex-
periment was repeated three times. *, p<0.05. 
Discussion 
Endothelial cell-cell junctions are instrumental in 
regulating the passage of leukocytes across the vas-
cular wall. Leukocytes cross the endothelium either 
through the cell-cell junctions, the paracellular route, 
or through the cell body of individual endothelial 
cells, the transcellular route [24]. Recently, Carman 
and colleagues showed that the majority of lympho-
cytes transmigrate by the paracellular route, but that 
there is a difference in the relative contribution of this 
route depending on the type of endothelium [25]. 
Lymphocytes that cross micro-vascular endothelium 
use the paracellular pathway for 70%, whereas more 
than 90% of the same lymphocytes choose this route 
when migrating across HUVEC. Irrespective of the 
type of endothelium, the majority of leukocytes prefer 
to migrate across the endothelial cell-cell junctions. 
Thus, the regulation of the cell-cell junctions during 
transmigration is important for efficient leukocyte 
extravasation. In this paper, we focused on the role of 
the adherens junctions and on the association between 
alpha- and beta-catenin in particular, in leukocyte 
transendothelial migration. 
Our results indicate that the connection between 
alpha- and beta-catenin is required for proper migra-
tion of leukocytes across endothelial cell monolayers. 
These results were surprising, because it has been 
reported that breaking the link between alpha- and 
beta-catenin weakens the cell-cell junctions [10,13], 
which conceivably would result in more efficient 
TEM. In line with this, our results show that S27D 
reduces TER of endothelial monolayers. However, 
S27D inhibits TEM. The resistance of the monolayer is 
measured by ECIS, known to be a highly sensitive 
technique. S27D induces a drop in the resistance, even 
though immuno-fluorescence images show that 
VE-cadherin and beta-catenin are still present at 
cell-cell junctions. However, compared to throm-
bin-induced drop in resistance, S27D induces a small 
drop in resistance. Thus, we conclude from these re-
sults that the signals that lead to the local weakening Int. J. Biol. Sci. 2009, 5 
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of the cell-cell junctions, to allow leukocyte TEM, re-
quire the presence of alpha-catenin in the 
VE-cadherin-catenin complex.  
VE-cadherin interacts with beta-catenin, which 
in turn is linked to the actin cytoskeleton through 
alpha-catenin. Loss of VE-cadherin function results in 
unstable endothelial junctions and an increase of 
leukocyte transmigration [6,8]. Sandig and colleagues 
already reported that the cadherin-catenin complex 
remains intact during diapedesis. This was judged by 
co-localization studies, where alpha-catenin 
co-localizes with VE-cadherin during the passage of a 
leukocyte [12]. It has been generally accepted that the 
strength of VE-cadherin-based cell-cell junctions de-
pends on the interaction of the cadherin-catenin com-
plex with the actin cytoskeleton [2]. A simple expla-
nation for the effect of S27D in the TEM assays is that 
under normal conditions, tension, which is generated 
through actomyosin-based contractility, weakens 
homotypic VE-cadherin interactions by pulling on 
alpha-catenin. When alpha-catenin is competed out of 
the cadherin-catenin complex by S27D, contractility 
towards cell-cell junctions is lost and the junctions 
remain relatively impermeable for leukocytes. The 
dogma that alpha-catenin links the cadherin-catenin 
complex to the actin cytoskeleton has been challenged 
recently by Drees and colleagues, showing that al-
pha-catenin cannot bind actin and beta-catenin at the 
same time [26]. Nevertheless, Abe and Takeichi re-
cently showed that EPLIN (Epithelial Protein Lost in 
Neoplasm) may be the linker between alpha-catenin 
and the actin cytoskeleton [27]. If this is also the case 
in endothelial cells remains to be investigated.  
Our data show that VE-cadherin still localizes at 
cell-cell junctions after S27D treatment. Moreover, 
S27D may increase VE-cadherin levels at junctions, 
although no change in total VE-cadherin protein is 
measured by Western blotting. This may point to a 
role for the alpha-beta-catenin interaction in 
VE-cadherin internalization. The expression of 
VE-cadherin on the surface is regulated by 
p120-catenin [21]. Alcaide and colleagues recently 
reported that over-expression of p120-catenin results 
in increased VE-cadherin expression at the cell-cell 
junctions and subsequent inhibition of leukocyte TEM 
[28]. Interestingly, the expression of the intracellular 
catenins was unaltered. Thus, these data suggest that 
p120-catenin-induced VE-cadherin is not bound to the 
catenins, which results in reduced TEM. This finding 
is in line with our data, in which VE-cadherin is un-
coupled from alpha-catenin by S27D, and may remain 
present at the plasma membrane, resulting in reduced 
TEM. However, our biochemical data indicate that 
S27D induces no difference in p120-catein and 
VE-cadherin binding. Gavard and Gutkind showed 
that VE-cadherin internalization can be regulated 
through clathrin-coated pits [29]. This pathway in-
volves beta-arrestin and Rac1 signalling. Whether 
S27D is involved in this pathway needs further re-
search. 
Together, our results show that the process of 
leukocyte transendothelial migration requires an in-
tact VE-cadherin-catenin complex, including al-
pha-catenin, to allow efficient passage of leukocytes. 
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